Iodixanol

Intravascular injection of iodixanol opacifies vessels in the path of flow of the contrast agent, permitting visualization of internal structures. In imaging of the body, iodinated contrast agents diffuse from the vascular into the extravascular space. In a normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with a disrupted bloodbrGeneral Iodixanol is a dimeric, isosmolar, nonionic, water soluble, and Iodinated x-ray contrast agent for intravascular administration. Intravascular injection of Iodixanol opacifies those vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant dilution and elimination occurs.Pharmacokinetics: Distribution In an in vitro human plasma study, Iodixanol did not bind to protein. The volume of distribution was 0.26 liky body weight, consistent with distribution to extracellular space. Metabolism Iodixanol metabolites have not been demonstrated. Excretion Plasma and urine levels suggest that body clearance of Iodixanol is primarily due to renal clearance. In adults, approximately 97% of the injected dose of Iodixanol is excreted unchanged in urine within 24 hours, with less than 2% excreted in feces within five days post-injection.Pharmacodynamics: As with other iodinated contrast agents, following administration of Visican Injection, the degree of enhancement is directly related to the iodine content in an administered dose; peak iodine plasma levels occur immediately following rapid intravascular injection. Iodine plasma levels fall rapidly within 5 to 10 minutes. This can be accounted for by the dilution in the vascular and extravascular fluid compartments.ain barrier, contrast agent accumulates in the interstitial space in the region of disruption.